Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the addition of infliximab to standard
primary therapy of intravenous immunoglobulin (IVIG) and high dose aspirin will reduce
resistance to therapy in acute Kawasaki disease (KD).